SK284712B6 - Použitie terapeuticky účinného množstva konvenčného humánneho leukocytového interferónu na výrobu lieku - Google Patents

Použitie terapeuticky účinného množstva konvenčného humánneho leukocytového interferónu na výrobu lieku Download PDF

Info

Publication number
SK284712B6
SK284712B6 SK1247-94A SK124794A SK284712B6 SK 284712 B6 SK284712 B6 SK 284712B6 SK 124794 A SK124794 A SK 124794A SK 284712 B6 SK284712 B6 SK 284712B6
Authority
SK
Slovakia
Prior art keywords
ifn
con
interferon
treatment
dose
Prior art date
Application number
SK1247-94A
Other languages
English (en)
Slovak (sk)
Other versions
SK124794A3 (en
Inventor
Lawrence M. Blatt
Milton W. Taylor
Original Assignee
Amgen Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25352556&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK284712(B6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc. filed Critical Amgen Inc.
Publication of SK124794A3 publication Critical patent/SK124794A3/sk
Publication of SK284712B6 publication Critical patent/SK284712B6/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SK1247-94A 1992-04-15 1993-04-14 Použitie terapeuticky účinného množstva konvenčného humánneho leukocytového interferónu na výrobu lieku SK284712B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/868,916 US5372808A (en) 1990-10-17 1992-04-15 Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
PCT/US1993/004471 WO1993021229A1 (en) 1992-04-15 1993-04-14 Methods and compositions for the treatment of diseases with interferon while reducing side effects

Publications (2)

Publication Number Publication Date
SK124794A3 SK124794A3 (en) 1995-04-12
SK284712B6 true SK284712B6 (sk) 2005-09-08

Family

ID=25352556

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1247-94A SK284712B6 (sk) 1992-04-15 1993-04-14 Použitie terapeuticky účinného množstva konvenčného humánneho leukocytového interferónu na výrobu lieku

Country Status (27)

Country Link
US (1) US5372808A (no)
EP (3) EP1419782A1 (no)
JP (2) JPH07505894A (no)
KR (1) KR950701350A (no)
CN (1) CN1098103C (no)
AT (1) ATE254926T1 (no)
AU (1) AU683214B2 (no)
CA (1) CA2118121C (no)
CZ (1) CZ247194A3 (no)
DE (1) DE69333321T3 (no)
DK (1) DK0911033T4 (no)
ES (1) ES2210864T5 (no)
HK (1) HK1018595A1 (no)
HU (1) HU227310B1 (no)
IL (1) IL105366A (no)
MX (1) MX9302160A (no)
NO (1) NO318643B1 (no)
NZ (1) NZ252871A (no)
PT (1) PT911033E (no)
RO (1) RO115700B1 (no)
RU (1) RU2128056C1 (no)
SG (1) SG52443A1 (no)
SK (1) SK284712B6 (no)
TW (1) TW265265B (no)
UA (1) UA44223C2 (no)
WO (1) WO1993021229A1 (no)
ZA (1) ZA932641B (no)

Families Citing this family (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US20020177688A1 (en) * 1988-12-22 2002-11-28 Kirin-Amgen, Inc., Chemically-modified G-CSF
ATE135370T1 (de) * 1988-12-22 1996-03-15 Kirin Amgen Inc Chemisch modifizierte granulocytenkolonie erregender faktor
US5906816A (en) * 1995-03-16 1999-05-25 University Of Florida Method for treatment of autoimmune diseases
US6372206B1 (en) * 1989-03-02 2002-04-16 University Of Florida Orally-administered interferon-TAU compositions and methods
US5372808A (en) † 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
RU2129437C1 (ru) * 1992-02-10 1999-04-27 Интерферон Сайнс Инк. Композиция альфа-интерферона и способ ее получения из лейкоцитов крови человека
US5676942A (en) * 1992-02-10 1997-10-14 Interferon Sciences, Inc. Composition containing human alpha interferon species proteins and method for use thereof
US5789551A (en) * 1993-06-11 1998-08-04 Pestka Biomedical Laboratories, Inc. Human leukocyte interferon Hu-IFN-α001
US6001589A (en) * 1993-06-11 1999-12-14 Pbl Biomedical Laboratories, Inc. Method of identifying proteins modified by disease states related thereto
WO1995015177A2 (en) * 1993-12-02 1995-06-08 President And Fellows Of Harvard College Improved efficacy of alpha-helical cytokines
EP1090645B1 (en) * 1994-02-08 2005-12-07 Amgen Inc., Oral delivery of chemically modified proteins
US20030053982A1 (en) * 1994-09-26 2003-03-20 Kinstler Olaf B. N-terminally chemically modified protein compositions and methods
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
IL116730A0 (en) * 1995-01-13 1996-05-14 Amgen Inc Chemically modified interferon
JP3104257B2 (ja) * 1995-08-30 2000-10-30 東レ株式会社 心疾患治療剤
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
EP0858343B1 (en) 1995-11-02 2004-03-31 Schering Corporation Continuous low-dose cytokine infusion therapy
US5739313A (en) * 1995-11-13 1998-04-14 Regents Of The University Of Minnesota Radionuclide labeling of vitamin B12 and coenzymes thereof
US20030026779A1 (en) * 1999-10-15 2003-02-06 Liming Yu Treatment of tumors and viral infections with a hybrid conjugate of interferon and an immunoglobulin Fc
US5980884A (en) * 1996-02-05 1999-11-09 Amgen, Inc. Methods for retreatment of patients afflicted with Hepatitis C using consensus interferon
BR9709068A (pt) * 1996-05-09 2000-01-11 Pharma Pacific Pty Ltd Processo de tratamento.
AUPN976596A0 (en) * 1996-05-09 1996-05-30 Pharma Pacific Pty Ltd Stimulation of host defence mechanisms
US5831062A (en) * 1996-05-09 1998-11-03 Amgen Inc. Use of the human interferon consensus gene for gene therapy
US20030190307A1 (en) * 1996-12-24 2003-10-09 Biogen, Inc. Stable liquid interferon formulations
US6017876A (en) 1997-08-15 2000-01-25 Amgen Inc. Chemical modification of granulocyte-colony stimulating factor (G-CSF) bioactivity
US6013253A (en) * 1997-08-15 2000-01-11 Amgen, Inc. Treatment of multiple sclerosis using consensus interferon and IL-1 receptor antagonist
US6541033B1 (en) 1998-06-30 2003-04-01 Amgen Inc. Thermosensitive biodegradable hydrogels for sustained delivery of leptin
US6432398B1 (en) * 1998-09-29 2002-08-13 W. Robert Fleischmann Methods of treating diseased cells
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
US6451346B1 (en) * 1998-12-23 2002-09-17 Amgen Inc Biodegradable pH/thermosensitive hydrogels for sustained delivery of biologically active agents
RU2140285C1 (ru) * 1999-01-25 1999-10-27 Гапонюк Петр Яковлевич Противовирусное средство - капли в нос "гриппферон"
HU228488B1 (en) * 1999-01-29 2013-03-28 Amgen Inc Gcsf conjugates
US6806363B1 (en) 1999-04-16 2004-10-19 Mayo Foundation For Medical Education & Research Cobalamin conjugates useful as antitumor agents
US8106098B2 (en) * 1999-08-09 2012-01-31 The General Hospital Corporation Protein conjugates with a water-soluble biocompatible, biodegradable polymer
US7591995B2 (en) * 1999-10-15 2009-09-22 Mayo Foundation For Medical Education And Research Cobalamin conjugates useful as imaging and therapeutic agents
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
JP5230052B2 (ja) 2000-05-26 2013-07-10 イデニクス（ケイマン）リミテツド フラビウイルスおよびペスチウイルス治療のための方法および組成物
US7105154B2 (en) * 2000-07-19 2006-09-12 Pepgen Corporation Method of treatment using interferon-tau
AU2002243438A1 (en) 2000-10-25 2002-07-24 Mayo Foundation For Medical Education And Research Transcobalamin binding conjugates useful for treating abnormal cellular proliferation
AU2002227252A1 (en) * 2000-12-01 2002-06-11 Cornell Research Foundation Animal model for flaviviridae infection
US20050079579A1 (en) * 2001-02-28 2005-04-14 Guangwen Wei Uses of spatial configuration to modulate protein function
CN1245215C (zh) * 2001-02-28 2006-03-15 四川省生物工程研究中心 重组高效复合干扰素用作乙型肝炎表面抗原和e抗原抑制剂
US20060035327A1 (en) * 2001-02-28 2006-02-16 Guangwen Wei Recombinant super-compound interferon and uses thereof
US8551469B2 (en) * 2001-02-28 2013-10-08 Superlab Far East Limited Treatment of tumors and viral diseases with recombinant interferon alpha
US20030104996A1 (en) * 2001-08-30 2003-06-05 Tiansheng Li L-methionine as a stabilizer for NESP/EPO in HSA-free formulations
EP1435974A4 (en) * 2001-09-28 2006-09-06 Idenix Cayman Ltd METHOD AND COMPOSITIONS FOR TREATING HEPATITIS C VIRUS WITH 4'-MODIFIED NUCLEOSIDES
EP1435973A4 (en) * 2001-09-28 2007-05-02 Mayo Foundation SIMULTANEOUS ADMINISTRATION OF A TRANSPORT PROTEIN WITH CONJUGATED COBALAMINE FOR THE DISTRIBUTION OF MEDICINAL PRODUCTS
PL369129A1 (en) * 2001-09-28 2005-04-18 Intermune, Inc. Method for treating hepatitis c virus infection in treatment failure patients
KR20040037191A (ko) * 2001-09-28 2004-05-04 인터뮨, 인크. 치료 실패 환자에서 ｃ형 간염 바이러스 감염의 치료 방법
KR20050030886A (ko) * 2001-10-05 2005-03-31 인터뮨, 인크. 다단계 인터페론 전달 프로필로 간염 바이러스 감염의 치료 방법
WO2003049760A1 (en) * 2001-12-07 2003-06-19 Intermune, Inc. Compositions and method for treating hepatitis virus infection
CA2472588A1 (en) * 2002-01-16 2003-07-31 Pepgen Corporation Oral administration of interferon-tau
US20040063912A1 (en) * 2002-03-15 2004-04-01 The Brigham And Women's Hospital, Inc. Central airway administration for systemic delivery of therapeutics
US20030191056A1 (en) 2002-04-04 2003-10-09 Kenneth Walker Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
NZ537662A (en) 2002-06-28 2007-10-26 Idenix Cayman Ltd 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
WO2004002422A2 (en) 2002-06-28 2004-01-08 Idenix (Cayman) Limited 2’-c-methyl-3’-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
TW200500374A (en) 2002-06-28 2005-01-01 Idenlx Cayman Ltd 2' and 3' -nucleoside produrgs for treating flavivridae infections
GB0215293D0 (en) * 2002-07-03 2002-08-14 Rega Foundation Viral inhibitors
CA2506129C (en) 2002-11-15 2015-02-17 Idenix (Cayman) Limited 2'-branched nucleosides and flaviviridae mutation
US7314613B2 (en) 2002-11-18 2008-01-01 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
AU2003300901A1 (en) 2002-12-12 2004-06-30 Idenix (Cayman) Limited Process for the production of 2'-branched nucleosides
EP1599171A2 (en) * 2003-02-28 2005-11-30 Intermune, Inc. Combination therapy for treating alphavirus infection and liver fibrosis
US20070077225A1 (en) * 2003-02-28 2007-04-05 Blatt Lawrence M Continuous delivery methods for treating hepatitis virus infection
WO2005003147A2 (en) 2003-05-30 2005-01-13 Pharmasset, Inc. Modified fluorinated nucleoside analogues
WO2005009418A2 (en) * 2003-07-25 2005-02-03 Idenix (Cayman) Limited Purine nucleoside analogues for treating diseases caused by flaviviridae including hepatitis c
SI2325202T1 (sl) * 2003-08-28 2015-02-27 Superlab Far East Limited Uporabe interferonov s spremenjeno prostorsko strukturo
KR20060130009A (ko) 2003-08-28 2006-12-18 휴이양테크 (유에스에이), 인크. 변경된 공간 구조를 갖는 인터페론의 용도
US7585647B2 (en) * 2003-08-28 2009-09-08 Guangwen Wei Nucleic acid encoding recombinant interferon
NZ546347A (en) 2003-10-14 2009-11-27 Intermune Inc Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of HCV replication
US7648998B2 (en) * 2003-12-22 2010-01-19 K.U. Leuven Research & Development Imidazo 4,5-c pyridine compounds and methods of antiviral treatment
CA2552241C (en) 2003-12-30 2013-10-01 Durect Corporation Co-polymeric devices for controlled release of active agents
CN1980657A (zh) 2004-05-05 2007-06-13 耶鲁大学 新颖的抗病毒赛菊宁黄质类似物
CA2566247A1 (en) 2004-05-19 2005-12-01 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
CN101023094B (zh) 2004-07-21 2011-05-18 法莫赛特股份有限公司 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
SI3109244T1 (sl) 2004-09-14 2019-06-28 Gilead Pharmasset Llc Priprava 2'fluoro-2'-alkil-substituiranih ali drugih neobvezno substituiranih ribofuranozil pirimidinov in purinov in njihovih derivatov
EP1679065A1 (en) * 2005-01-07 2006-07-12 OctoPlus Sciences B.V. Controlled release compositions for interferon based on PEGT/PBT block copolymers
CA2597317C (en) * 2005-03-09 2018-01-02 Guangwen Wei Uses of recombinant super-compound interferons
JP4516863B2 (ja) * 2005-03-11 2010-08-04 株式会社ケンウッド 音声合成装置、音声合成方法及びプログラム
MX2007014524A (es) 2005-05-18 2008-02-07 Maxygen Inc Polipeptidos desarrollados de interferon-alfa.
US20090148407A1 (en) 2005-07-25 2009-06-11 Intermune, Inc. Novel Macrocyclic Inhibitors of Hepatitis C Virus Replication
ATE493409T1 (de) 2005-10-11 2011-01-15 Intermune Inc Verbindungen und verfahren zur inhibierung der replikation des hepatitis-c-virus
WO2007075876A2 (en) 2005-12-23 2007-07-05 Idenix Pharmaceuticals, Inc. Process for preparing a synthetic intermediate for preparation of branched nucleosides
CA2648077A1 (en) * 2006-03-31 2007-11-08 Schering Corporation Parenteral low dose type 1 interferons for bladder cancer
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
CN101525381B (zh) 2008-03-04 2012-04-18 北京百川飞虹生物科技有限公司 一种重组复合干扰素及其表达载体的构建和表达
TW200946541A (en) * 2008-03-27 2009-11-16 Idenix Pharmaceuticals Inc Solid forms of an anti-HIV phosphoindole compound
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
SG172363A1 (en) 2008-12-23 2011-07-28 Pharmasset Inc Synthesis of purine nucleosides
WO2010075517A2 (en) * 2008-12-23 2010-07-01 Pharmasset, Inc. Nucleoside analogs
CL2009002207A1 (es) 2008-12-23 2011-02-18 Gilead Pharmasset Llc Compuestos derivados de 3-hidroxi-5-(9h-purin-9-il)tetrahidrofuran-2-il, inhibidor de la replicacion de arn viral dependiente de arn; composicion farmaceutica; uso para el tratamiento de hepatitis c.
TWI583692B (zh) 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 核苷磷醯胺
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
WO2010142017A1 (en) 2009-06-09 2010-12-16 Defyrus, Inc . Administration of interferon for prophylaxis against or treatment of pathogenic infection
EP2459211A1 (en) 2009-07-31 2012-06-06 Medtronic, Inc. Continuous subcutaneous administration of interferon- to hepatitis c infected patients
CN102101886A (zh) 2009-12-18 2011-06-22 四川辉阳生命工程股份有限公司 构象改变的重组干扰素晶体、其三维结构及应用
AP3515A (en) 2010-03-31 2016-01-11 Gilead Pharmasset Llc Nucleoside phosphoramidates
US8563530B2 (en) 2010-03-31 2013-10-22 Gilead Pharmassel LLC Purine nucleoside phosphoramidate
CN102711871A (zh) 2010-06-16 2012-10-03 麦德托尼克公司 用于稳定药物递送装置中的药物的阻尼系统
PT2621519T (pt) 2010-09-28 2017-10-04 Aegerion Pharmaceuticals Inc Polipéptido de fusão de leptina-abd com duração de ação melhorada
JP6069215B2 (ja) 2010-11-30 2017-02-01 ギリアド ファーマセット エルエルシー 化合物
BRPI1107312B1 (pt) * 2011-11-25 2021-09-08 Universidade Federal De Santa Catarina Composto de acil-hidrazona
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
US8809354B2 (en) 2011-12-31 2014-08-19 Sheikh Riazuddin 3-amino-2-(4-nitrophenyl)-4-(3H)-quinazolinone or derivatives thereof for treating or preventing antiviral infections
TWI726291B (zh) 2013-01-07 2021-05-01 英屬維爾京群島商遠東超級實驗室有限公司 通過干擾素的經皮和/或經粘膜給藥治療骨癌、皮膚癌、皮下癌、粘膜癌和/或粘膜下癌的方法和組合物
ES2900570T3 (es) 2013-08-27 2022-03-17 Gilead Pharmasset Llc Formulación de combinación de dos compuestos antivirales

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES8302778A1 (es) † 1980-11-10 1983-02-01 Genentech Inc Un procedimiento para producir un polipeptido antiviral.
US6936694B1 (en) * 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
SE8502430L (sv) † 1985-05-15 1986-11-16 Kabivitrum Ab En cdna-molekyl som kodar for expressionen av en polypeptid av typen interferon alfa, en bakteriell eller celluler verd transformerad med en sadan molekyl och en polypeptid som uppvisar interferonaktivetet framstelld me
US4885166A (en) † 1985-06-11 1989-12-05 Ciba-Geigy Corporation Hybrid interferons
US5372808A (en) † 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
SG52537A1 (en) * 1990-10-17 1998-09-28 Amgen Inc Methods and compositions for the treatment of cell proliferation disorders

Also Published As

Publication number Publication date
EP0641359A4 (en) 1995-10-04
WO1993021229A1 (en) 1993-10-28
CZ247194A3 (en) 1995-04-12
HUT70216A (en) 1995-09-28
EP1419782A1 (en) 2004-05-19
EP0911033A3 (en) 1999-05-19
UA44223C2 (uk) 2002-02-15
ES2210864T5 (es) 2010-03-09
IL105366A0 (en) 1993-08-18
KR950701350A (ko) 1995-03-23
EP0641359A1 (en) 1995-03-08
SK124794A3 (en) 1995-04-12
DE69333321T3 (de) 2010-03-18
NZ252871A (en) 1997-08-22
TW265265B (no) 1995-12-11
AU4293493A (en) 1993-11-18
KR100321467B1 (no) 2008-11-13
ES2210864T3 (es) 2004-07-01
CA2118121A1 (en) 1993-10-28
RU2128056C1 (ru) 1999-03-27
HK1018595A1 (en) 1999-12-30
HU9402979D0 (en) 1995-02-28
DE69333321D1 (de) 2004-01-08
US5372808A (en) 1994-12-13
HU227310B1 (en) 2011-03-28
EP0911033A2 (en) 1999-04-28
NO318643B1 (no) 2005-04-25
ZA932641B (en) 1993-10-22
ATE254926T1 (de) 2003-12-15
DK0911033T3 (da) 2004-03-29
DE69333321T2 (de) 2004-09-16
NO943901D0 (no) 1994-10-14
CN1081909A (zh) 1994-02-16
IL105366A (en) 1999-11-30
SG52443A1 (en) 1998-09-28
EP0911033B2 (en) 2009-11-18
DK0911033T4 (da) 2010-03-22
JP2005029561A (ja) 2005-02-03
AU683214B2 (en) 1997-11-06
CA2118121C (en) 2005-08-02
PT911033E (pt) 2004-04-30
JPH07505894A (ja) 1995-06-29
MX9302160A (es) 1994-05-31
RO115700B1 (ro) 2000-05-30
CN1098103C (zh) 2003-01-08
EP0911033B1 (en) 2003-11-26
NO943901L (no) 1994-10-14

Similar Documents

Publication Publication Date Title
US5372808A (en) Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
JP3496937B2 (ja) コンセンサスヒトインターフェロンを含有する細胞増殖障害治療用の医用組成物
NZ259584A (en) Cancer treatment using interleukin 10 activated peripheral blood mononuclear cells optionally combined with il-10 alone or in combination with il-2 or alpha interferon (alpha-ifn), to stimulate peripheral blood mononuclear cells
EP0563060B1 (en) Use of IL-4 and TNF for the preparation of a medicament for the treatment of tumour cells
Oritani et al. Limitin: an interferon-like cytokine without myeloerythroid suppressive properties
US5871725A (en) Use of IL-10 to stimulate peripheral blood mononuclear cell cytolytic activity
CA1291706C (en) COMBINATION THERAPY USING INTERFERON-.beta. AND INTERLEUKIN-2
US20190374611A1 (en) Methods and pharmaceutical compositions for the treatment patients suffering from myeloproliferative disorders
EP1471974B1 (en) Tumor necrosis factor combined with interferon in demyelinating diseases
KR20010024044A (ko) 만성씨형간염의치료에서동시적으로,개별적으로또는연속적으로사용하기위한,아이에프엔-알파와아만타딘이조합되어사용되는약제
Revel STRUCTURE, DIFFERENTIAL ACTIONS, AND

Legal Events

Date Code Title Description
MK4A Expiry of patent

Expiry date: 20130414